Importantly, two S1R ligands, such as Blarcamesine and Pridopidine, are in advanced clinical phases for the treatment of AD and Huntington’s Disease (HD), respectively, and their use in related pathologies is also under investigation [26,27,28]. This evidence concerns the gene TMBIM4 and Huntington disease.